HK1215534A1 - 使用藥理陪伴分子以增強神經節苷脂沉積症之活動用作治療阿爾茨海默氏症的方法 - Google Patents

使用藥理陪伴分子以增強神經節苷脂沉積症之活動用作治療阿爾茨海默氏症的方法

Info

Publication number
HK1215534A1
HK1215534A1 HK16103501.8A HK16103501A HK1215534A1 HK 1215534 A1 HK1215534 A1 HK 1215534A1 HK 16103501 A HK16103501 A HK 16103501A HK 1215534 A1 HK1215534 A1 HK 1215534A1
Authority
HK
Hong Kong
Prior art keywords
gangliosidases
activity
increase
alzheimers disease
pharmacological chaperones
Prior art date
Application number
HK16103501.8A
Other languages
English (en)
Inventor
Wustman Brandon
Valenzano Kenneth
Boyd Robert
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of HK1215534A1 publication Critical patent/HK1215534A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HK16103501.8A 2009-10-19 2016-03-24 使用藥理陪伴分子以增強神經節苷脂沉積症之活動用作治療阿爾茨海默氏症的方法 HK1215534A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25279909P 2009-10-19 2009-10-19

Publications (1)

Publication Number Publication Date
HK1215534A1 true HK1215534A1 (zh) 2016-09-02

Family

ID=43900619

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13102468.4A HK1175400A1 (zh) 2009-10-19 2013-02-27 使用藥理陪伴分子以增強神經節苷脂沉積症之活動用作治療阿爾茨海默氏症的方法
HK16103501.8A HK1215534A1 (zh) 2009-10-19 2016-03-24 使用藥理陪伴分子以增強神經節苷脂沉積症之活動用作治療阿爾茨海默氏症的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13102468.4A HK1175400A1 (zh) 2009-10-19 2013-02-27 使用藥理陪伴分子以增強神經節苷脂沉積症之活動用作治療阿爾茨海默氏症的方法

Country Status (10)

Country Link
US (2) US9044437B2 (zh)
EP (2) EP2957295B1 (zh)
JP (2) JP6061677B2 (zh)
CA (1) CA2778049C (zh)
DK (1) DK2490712T3 (zh)
ES (2) ES2549504T3 (zh)
HK (2) HK1175400A1 (zh)
PL (1) PL2490712T3 (zh)
PT (1) PT2490712E (zh)
WO (1) WO2011049787A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2814178T3 (es) * 2009-10-19 2021-03-26 Amicus Therapeutics Inc Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
DK2751279T3 (da) 2011-08-31 2017-11-20 St Jude Children's Res Hospital Fremgangsmåder og sammensætninger til påvisning af niveauet af lysosomal exocytose-aktivitet og fremgangsmåder til anvendelse
AU2013240486B2 (en) * 2012-03-27 2017-10-26 Amicus Therapeutics, Inc. Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
US9994589B2 (en) 2015-12-14 2018-06-12 Amicus Therapeutics, Inc. Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy
JP7445251B2 (ja) * 2017-12-28 2024-03-07 国立大学法人 熊本大学 アルツハイマー病予防剤又は治療剤、アルツハイマー病予防用又は治療用組成物、及び方法
EP4208438A1 (en) * 2020-08-28 2023-07-12 The Regents of the University of California Compositions and methods for treating amyloid-related conditions
WO2023288252A1 (en) * 2021-07-13 2023-01-19 Truebinding, Inc. Methods of preventing protein aggregation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004103368A1 (en) * 2003-05-22 2004-12-02 The Hospital For Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
BRPI0713442A2 (pt) * 2006-06-23 2012-03-06 Amicus Therapeutics, Inc. Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase
EP2150254A4 (en) * 2007-04-26 2010-11-10 Amicus Therapeutics Inc DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
WO2011011181A1 (en) 2009-07-01 2011-01-27 Amicus Therapeutics, Inc. Pharmacological chaperones for the treatment of alzheimer's disease
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses

Also Published As

Publication number Publication date
EP2957295B1 (en) 2017-08-02
DK2490712T3 (en) 2015-10-05
JP2013508371A (ja) 2013-03-07
US9931353B2 (en) 2018-04-03
JP6204961B2 (ja) 2017-09-27
EP2490712A1 (en) 2012-08-29
JP6061677B2 (ja) 2017-01-18
JP2016041741A (ja) 2016-03-31
EP2957295A1 (en) 2015-12-23
WO2011049787A1 (en) 2011-04-28
US20120309788A1 (en) 2012-12-06
US9044437B2 (en) 2015-06-02
PT2490712E (pt) 2015-10-27
PL2490712T3 (pl) 2015-12-31
EP2490712B1 (en) 2015-07-08
CA2778049A1 (en) 2011-04-28
ES2549504T3 (es) 2015-10-28
US20150374733A1 (en) 2015-12-31
EP2490712A4 (en) 2013-06-12
CA2778049C (en) 2018-12-04
HK1175400A1 (zh) 2013-07-05
ES2646099T3 (es) 2017-12-12

Similar Documents

Publication Publication Date Title
HK1215534A1 (zh) 使用藥理陪伴分子以增強神經節苷脂沉積症之活動用作治療阿爾茨海默氏症的方法
HK1217763A1 (zh) 用於治療疾病的方法
ZA201207565B (en) System for treatment of biomass to facilitate the production of ethanol
EP2639297A4 (en) PROCESS FOR THE PRODUCTION OF PLURIPOTENT STEM CELLS DERIVED FROM PERIPHERAL BLOOD MONOCYTES
HK1176870A1 (zh) 疾病的治療方法
GB201302929D0 (en) A method of treating alzheimers disease
PT2539352T (pt) Composições e métodos para tratar doenças cardíacas
WO2011011644A9 (en) Method to improve laser treatment of disease
EP2544686A4 (en) COMBINED METHODS FOR THE TREATMENT OF DISEASES
GB0904427D0 (en) Treatment of diseases related to hyperactivity of the complement system
ZA201108496B (en) System for treatment of biomass to facilitate the production of ethanol
EP2416803A4 (en) NEW METHODS OF TREATING INFLAMMATORY DISEASES
GB201020045D0 (en) Method for the treatment of biogas
GB0906161D0 (en) Treatment for energy utilization diseases
GB0908666D0 (en) Treatment of proteostatic disease
GB0900334D0 (en) Methods for improving biomass yield

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211008